TREM2 agonistic antibodies restore microglial phagocytosis and plaque compaction in Alzheimer's disease, particularly for R47H variant carriers with ~3-fold increased AD risk. Multiple agonistic antibodies (AL002c, 4D9) are in development targeting the SYK/PLCγ2/CARD9 cascade. Critical uncertainties include biphasic dose-response pharmacology, appropriate mouse model design (conditional knockout rather than constitutive knockout), and the temporal window for therapeutic intervention given biphas
Bayesian fine-mapping of the top 25 AD GWAS loci will identify credible sets significantly enriched for variants disrupting microglia-specific regulatory elements, reflecting microglial dysfunction as a central AD pathogenic mechanism. Credible sets at loci with known effector genes (APOE, TREM2, PLCG2) will be smaller (<10 variants) due to stronger functional constraints, while novel loci will have larger sets requiring integration with epigenomic data to prioritize causal variants. The highest
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
TREM2NeuroinflammationUnspecified Mechanism
Convergent signals
TREM2 recurs across 2 selected hypotheses with aligned directionality in neuroinflammation, unspecified mechanism.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
9/11
dimensions won
TREM2 Microglial Activation Rescues Amyl
3/11
dimensions won
AD fine-mapping identifies causal varian
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.75
0.00
Evidence
0.82
0.72
Novelty
0.60
0.68
Feasibility
0.62
0.85
Impact
0.85
0.00
Druggability
0.68
0.00
Safety
0.65
0.00
Competition
0.75
0.00
Data
0.72
0.00
Reproducible
0.65
0.00
KG Connect
0.50
0.50
Score Breakdown
Dimension
TREM2 Microglial Activation Re
AD fine-mapping identifies cau
Mechanistic
0.750
0.000
Evidence
0.820
0.720
Novelty
0.600
0.680
Feasibility
0.620
0.850
Impact
0.850
0.000
Druggability
0.680
0.000
Safety
0.650
0.000
Competition
0.750
0.000
Data
0.720
0.000
Reproducible
0.650
0.000
KG Connect
0.500
0.500
Evidence
TREM2 Microglial Activation Rescues Amyloid Clearance in AD
No evidence citations yet
AD fine-mapping identifies causal variants in microglia-spec
# Feasibility Assessment: Neurodegeneration Therapeutic Hypotheses
## Analytical Framework
This assessment evaluates each hypothesis across five domains:
1. **Druggability** — tractability of the ta...